VIENNA--(BUSINESS WIRE)--Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder, X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), today announced that Neil Kirby, Ph.D., President & Chief Executive Officer of Edimer, presented an update on the company’s lead compound, EDI200, to the International Ectodermal Dysplasia Meeting in Vienna, a gathering of 14 ectodermal dysplasia patient foundations from around the world. This meeting serves as a forum for the discussion of scientific and medical information about ectodermal dysplasias. XLHED affects primarily boys and, in its most severe form, is associated with serious and potentially life-threatening illness in infancy resulting from a lack of sweating leading to hyperthermia and from respiratory infections. In addition, affected individuals commonly have clinically significant abnormalities of teeth, hair, and tear ducts. There are currently no FDA-approved treatments for XLHED.
